Vyndaqel and Vyndamax are designed for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults.
The pharmaceutical agents reduce cardiovascular mortality and cardiovascular-related hospitalizations. They are transthyretin stabilizer tafamidis.
Most common side effects include urinary tract infection, vaginal infection, upper abdominal pain and diarrhea.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs